Wockhardt Limited has informed the Exchange about Investor Presentation
WOCKPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Wockhardt shared its June 2025 Investor Presentation highlighting strong FY25 results: total income of INR 3,033 Cr (up 5% YoY) and EBITDA of INR 418 Cr (up 67% YoY), with EBITDA margins expanding from 9% to 14%. The company drastically cut its net debt from INR 461 Cr to just INR 64 Cr, achieving a near-zero net debt-to-equity ratio of 0.01, supported by a INR 1,000 Cr QIP capital raise. Key pipeline updates include ZAYNICH (WCK 5222) completing global Phase III with 20% superiority over Meropenem, MIQNAF launched in India with Saudi BMP designation, and multiple biosimilars progressing. Management outlined a 3-5 year growth roadmap with ZAYNICH targeting a US$ 9 bn global opportunity and the diabetes biosimilars business expected to grow 20-25% as it doubles capacity.
Positive for shareholders: sharp EBITDA growth, dramatic deleveraging, and a visible multi-year growth pipeline in novel antibiotics and biosimilars could boost investor confidence and support the stock. However, near-term revenue growth of just 5% and dependence on upcoming US FDA approval for ZAYNICH (Q2 FY26 filing) remain key watchpoints.